Herantis Pharma plc sponsors first CDNF MANF Sympo

Herantis Pharma plc sponsors first CDNF MANF Symposium

Herantis Pharma Plc Press release 10 Jan 2017 at 9:00 am

Herantis Pharma plc ("Herantis") participates as a sponsor in organising the first scientific CDNF MANF Symposium. The Symposium will be held at the Stanford University in California on January 23-24, 2017. In addition to Herantis, several researchers from Herantis' academic partner, the University of Helsinki will present at the Symposium including professor Mart Saarma .

The CDNF and MANF proteins form a family of novel neurotrophic factors (NTFs) clearly distinct from conventional NTFs. The Symposium will focus on the research and development related to CDNF and MANF and their potential for the treatment of several different diseases. CDNF, patented internationally by Herantis, had advanced furthest of these NTFs toward clinical application.

Herantis will be represented at the Symposium by its Chief Scientific Officer Henri Huttunen , PhD. More details on the Symposium can be found on its web site https://lifesciences.knect365.com/amarantus/highlights .

Further information:

Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445 Company web site: www.herantis.com

About CDNF

CDNF, or Cerebral Dopamine Neurotrophic Factor, is an endoplasmic reticulum located and secreted protein with neuroprotective and neurorestorative properties, patented worldwide by Herantis.  Following a preclinical development program, which has showed it as efficacious in several preclinical models of Parkinson's disease, Herantis is preparing for a first-in-human clinical study of CDNF in the treatment of PD and has a preclinical development program for the treatment of ALS.

In preclinical studies including chronic toxicology studies, CDNF administration has been safe; CDNF has protected and regenerated midbrain dopamine-generating cells suggesting a potential for disease modification of PD; it has also shown efficacy in several non-motor symptoms in PD. In an ALS disease model CDNF has significantly increased survival and reduced symptoms. This suggests the potential to address unmet clinical needs in both PD and ALS. CDNF is based on research at the Institute of Biotechnology at the University of Helsinki, lead by professor Mart Saarma .

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our first-in-class assets are based on globally leading scientific research in their fields: CDNF for disease modification in neurodegenerative diseases, primarily Parkinson's and ALS; and Lymfactin® for breast cancer associated lymphedema, with potential also in primary lymphedema. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Main media www.herantis.com